239 related articles for article (PubMed ID: 29953856)
1. Benefits of long-term pilocarpine due to increased muscarinic acetylcholine receptor 3 in salivary glands.
Minagi HO; Ikai K; Araie T; Sakai M; Sakai T
Biochem Biophys Res Commun; 2018 Sep; 503(2):1098-1102. PubMed ID: 29953856
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren's syndrome.
Tomiita M; Takei S; Kuwada N; Nonaka Y; Saito K; Shimojo N; Kohno Y
Mod Rheumatol; 2010 Oct; 20(5):486-90. PubMed ID: 20517630
[TBL] [Abstract][Full Text] [Related]
3. The use of oral pilocarpine in xerostomia and Sjögren's syndrome.
Nusair S; Rubinow A
Semin Arthritis Rheum; 1999 Jun; 28(6):360-7. PubMed ID: 10406404
[TBL] [Abstract][Full Text] [Related]
4. A new medication for treatment of dry mouth in Sjögren's syndrome.
al-Hashimi I; Taylor SE
Tex Dent J; 2001 Apr; 118(3):262-6. PubMed ID: 11404944
[TBL] [Abstract][Full Text] [Related]
5. Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome.
Rhodus NL
Oral Dis; 1997 Jun; 3(2):93-8. PubMed ID: 9467349
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of cAMP-PKA Signaling Pathway Mediated by Shaoyao Gancao Decoction () on Regulation of Aquaporin 5 and Muscarinic Receptor 3 Levels in Sjögren's Syndrome.
Wang D; Zhao H; Li B; Sun Y; Wei DH
Chin J Integr Med; 2020 Jul; 26(7):502-509. PubMed ID: 32632716
[TBL] [Abstract][Full Text] [Related]
7. [Results of the treatment with oral pilocarpine in 100 patients with primary Sjögrens syndrome].
Brito-Zerón P; Ramos-Casals M; Nardi N; Font J
Med Clin (Barc); 2006 Apr; 126(16):637. PubMed ID: 16759558
[No Abstract] [Full Text] [Related]
8. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome.
Iwabuchi Y; Masuhara T
Gen Pharmacol; 1994 Jan; 25(1):123-9. PubMed ID: 7517901
[TBL] [Abstract][Full Text] [Related]
9. Systemic pilocarpine for treatment of xerostomia.
Berk L
Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1333-40. PubMed ID: 18798702
[TBL] [Abstract][Full Text] [Related]
10. Use of muscarinic agonists in the treatment of Sjögren's syndrome.
Fox RI; Konttinen Y; Fisher A
Clin Immunol; 2001 Dec; 101(3):249-63. PubMed ID: 11726216
[TBL] [Abstract][Full Text] [Related]
11. Effects of pilocarpine on salivary flow in patients with Sjogren's syndrome.
Fox PC; Mandel ID
Oral Surg Oral Med Oral Pathol; 1992 Sep; 74(3):315-8. PubMed ID: 1407993
[No Abstract] [Full Text] [Related]
12. Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome.
Rhodus NL; Schuh MJ
Oral Surg Oral Med Oral Pathol; 1991 Nov; 72(5):545-9. PubMed ID: 1745512
[TBL] [Abstract][Full Text] [Related]
13. Effect of Pilocarpine on impaired salivary secretion in patients with Sjögren's syndrome.
Jorkjend L; Bergenholtz A; Johansson AK; Johansson A
Swed Dent J; 2008; 32(2):49-56. PubMed ID: 18700333
[TBL] [Abstract][Full Text] [Related]
14. Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice.
Gautam D; Heard TS; Cui Y; Miller G; Bloodworth L; Wess J
Mol Pharmacol; 2004 Aug; 66(2):260-7. PubMed ID: 15266016
[TBL] [Abstract][Full Text] [Related]
15. A controlled release pilocarpine buccal insert in the treatment of Sjögren's syndrome.
Gibson J; Halliday JA; Ewert K; Robertson S
Br Dent J; 2007 Apr; 202(7):E17; discussion 404-5. PubMed ID: 17273177
[TBL] [Abstract][Full Text] [Related]
16. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group.
Vivino FB; Al-Hashimi I; Khan Z; LeVeque FG; Salisbury PL; Tran-Johnson TK; Muscoplat CC; Trivedi M; Goldlust B; Gallagher SC
Arch Intern Med; 1999 Jan; 159(2):174-81. PubMed ID: 9927101
[TBL] [Abstract][Full Text] [Related]
17. Salivary gland dysfunction and xerostomia in Sjögren's syndrome.
Jensen SB; Vissink A
Oral Maxillofac Surg Clin North Am; 2014 Feb; 26(1):35-53. PubMed ID: 24287192
[TBL] [Abstract][Full Text] [Related]
18. M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice.
Nakamura T; Matsui M; Uchida K; Futatsugi A; Kusakawa S; Matsumoto N; Nakamura K; Manabe T; Taketo MM; Mikoshiba K
J Physiol; 2004 Jul; 558(Pt 2):561-75. PubMed ID: 15146045
[TBL] [Abstract][Full Text] [Related]
19. New epitopes and function of anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome.
Tsuboi H; Matsumoto I; Wakamatsu E; Nakamura Y; Iizuka M; Hayashi T; Goto D; Ito S; Sumida T
Clin Exp Immunol; 2010 Oct; 162(1):53-61. PubMed ID: 20731676
[TBL] [Abstract][Full Text] [Related]
20. Approaches to the treatment of Sjögren's syndrome.
Fox RI; Michelson P
J Rheumatol Suppl; 2000 Dec; 61():15-21. PubMed ID: 11128699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
